190 related articles for article (PubMed ID: 17303956)
1. Luteinizing hormone-releasing hormone analogue-induced cataract in a patient with prostate cancer.
Al-Enezi A; Kehinde EO; Behbehani AM; Sheikh ZA
Med Princ Pract; 2007; 16(2):161-3. PubMed ID: 17303956
[TBL] [Abstract][Full Text] [Related]
2. Randomised crossover trial to assess the tolerability of LHRH analogue administration.
Williams G; Lindsay S; Bowsher WG
Prostate Cancer Prostatic Dis; 2003; 6(2):187-9. PubMed ID: 12806381
[TBL] [Abstract][Full Text] [Related]
3. [Skin reaction induced by subcutaneous injection of LH-RH analogue].
Segawa N; Nishida T; Hamada S; Azuma H; Katsuoka Y; Nozaki K; Tsuji M
Hinyokika Kiyo; 2007 Oct; 53(10):695-8. PubMed ID: 18018584
[TBL] [Abstract][Full Text] [Related]
4. Testosterone recovery and changes in bone mineral density after stopping long-term luteinizing hormone-releasing hormone analogue therapy in osteoporotic patients with prostate cancer.
Weston R; Hussain A; George E; Parr NJ
BJU Int; 2005 Apr; 95(6):776-9. PubMed ID: 15794781
[TBL] [Abstract][Full Text] [Related]
5. Severe flare-up in a prostate cancer patient treated with luteinizing hormone-releasing hormone analogue depot.
Shimizu T; Shibata Y; Uchida T; Satoh J
Hinyokika Kiyo; 1993 Oct; 39(10):953-5. PubMed ID: 8266863
[TBL] [Abstract][Full Text] [Related]
6. [Recent advance in luteinizing hormone-releasing hormone analogue therapy in management of prostate cancer].
Kawai K; Akaza H
Nihon Rinsho; 1998 Aug; 56(8):2108-13. PubMed ID: 9750517
[TBL] [Abstract][Full Text] [Related]
7. Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer.
Fujii Y; Yonese J; Kawakami S; Yamamoto S; Okubo Y; Fukui I
BJU Int; 2008 May; 101(9):1096-100. PubMed ID: 18190637
[TBL] [Abstract][Full Text] [Related]
8. Does neoadjuvant hormone therapy for early prostate cancer affect cognition? Results from a pilot study.
Jenkins VA; Bloomfield DJ; Shilling VM; Edginton TL
BJU Int; 2005 Jul; 96(1):48-53. PubMed ID: 15963119
[TBL] [Abstract][Full Text] [Related]
9. Bicalutamide vs cyproterone acetate in preventing flare with LHRH analogue therapy for prostate cancer--a pilot study.
Sugiono M; Winkler MH; Okeke AA; Benney M; Gillatt DA
Prostate Cancer Prostatic Dis; 2005; 8(1):91-4. PubMed ID: 15711607
[TBL] [Abstract][Full Text] [Related]
10. Treatment of advanced prostatic carcinoma with a slow release depot LHRH analogue (Zoladex depot).
Lukkarinen O; Kontturi M
Scand J Urol Nephrol Suppl; 1988; 110():109-12. PubMed ID: 2973121
[TBL] [Abstract][Full Text] [Related]
11. Serum testosterone recovery after cessation of long-term luteinizing hormone-releasing hormone agonist in patients with prostate cancer.
Bong GW; Clarke HS; Hancock WC; Keane TE
Urology; 2008 Jun; 71(6):1177-80. PubMed ID: 18279929
[TBL] [Abstract][Full Text] [Related]
12. Resistance to luteinizing hormone releasing hormone agonist therapy for metastatic prostate cancer.
Curry EA; Sweeney CJ
J Urol; 2002 Jul; 168(1):193. PubMed ID: 12050525
[No Abstract] [Full Text] [Related]
13. Does needle size matter? Patient experience of luteinising hormone-releasing hormone analogue injection.
Montgomery BS; Borwell JP; Higgins DM
Prostate Cancer Prostatic Dis; 2005; 8(1):66-8. PubMed ID: 15700050
[TBL] [Abstract][Full Text] [Related]
14. [A new LH-RH agonist for treatment of prostate cancer, 3-month controlled-release formulation of goserelin acetate (Zoladex LA 10.8 mg depot)--outline of pre-clinical and clinical studies].
Tsukagoshi S
Gan To Kagaku Ryoho; 2002 Sep; 29(9):1675-87. PubMed ID: 12355959
[TBL] [Abstract][Full Text] [Related]
15. Goserelin (Zoladex) or orchiectomy in metastatic prostate cancer? A quality of life and cost-effectiveness analysis.
Nygård R; Norum J; Due J
Anticancer Res; 2001; 21(1B):781-8. PubMed ID: 11299844
[TBL] [Abstract][Full Text] [Related]
16. A new long acting formulation of the luteinizing hormone-releasing hormone analogue goserelin: results of studies in prostate cancer.
Debruyne FM; Dijkman GA; Lee DC; Witjes WP; del Moral F; Karthaus HF; van der Mejden AP; Plasman JW; Pull HC; Kums JJ; Idema JG; Hoefakker JW; Heijbroek RP; Kil PJ; Khoe GS
J Urol; 1996 Apr; 155(4):1352-4. PubMed ID: 8632572
[TBL] [Abstract][Full Text] [Related]
17. Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer.
Yri OE; Bjoro T; Fossa SD
Eur Urol; 2006 Jan; 49(1):54-8; discussion 58. PubMed ID: 16314038
[TBL] [Abstract][Full Text] [Related]
18. Roles of the urologist and nurse from the perspective of patients with prostate cancer receiving luteinizing hormone-releasing hormone analogue therapy.
Lebret T; Bouregba A
BJU Int; 2008 Nov; 102(10):1419-24. PubMed ID: 18549431
[TBL] [Abstract][Full Text] [Related]
19. [LHRH analogues for the treatment of prostate cancer: an evidence level-based analysis].
Pfitzenmaier J; Altwein JE
Aktuelle Urol; 2009 Mar; 40(2):100-8. PubMed ID: 19253209
[TBL] [Abstract][Full Text] [Related]
20. Delayed pituitary apoplexy in patient with advanced prostate cancer treated with gonadotrophin-releasing hormone agonists.
Sinnadurai M; Cherukuri RK; Moses RG; Nasser E
J Clin Neurosci; 2010 Sep; 17(9):1201-3. PubMed ID: 20605467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]